EsoBiotec Overview
- Year Founded
-
2020
- Status
-
Acquired/Merged
- Employees
-
12
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1B
EsoBiotec General Information
Description
Developer of immunotherapies designed to make cancer treatments more accessible, effective, and affordable. The company develops drugs and therapeutics that are cost-effective to maximize accessibility to empower the human body to tackle cancer by bringing in vivo engineering of cells to patients, enabling patients to have access to cancer treatments at lower costs.
Contact Information
Website
www.esobiotec.com(Operating Subsidiary)
Corporate Office
- Rue André Dumont 5
- 1435 Mont-Saint-Guibert
- 6041 Charleroi
- Belgium
Corporate Office
- Rue André Dumont 5
- 1435 Mont-Saint-Guibert
- 6041 Charleroi
- Belgium
EsoBiotec Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 19-May-2025 | $1B | Completed | Generating Revenue | ||
| 4. Early Stage VC (Series A) | 27-Aug-2024 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 14-Jun-2022 | Completed | Generating Revenue | |||
| 2. Seed Round | 30-Sep-2021 | $2.65M | $2.65M | Completed | Generating Revenue | |
| 1. Grant | 01-Jan-2021 | $3.65M | Completed | Generating Revenue |
EsoBiotec Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preference Shares |
EsoBiotec Patents
EsoBiotec Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024308616-A1 | Viral vector and producer cell | Pending | 30-Jun-2023 | ||
| EP-4484563-A1 | Viral vector and producer cell | Active | 30-Jun-2023 | ||
| EP-4484563-B1 | Viral vector and producer cell | Active | 30-Jun-2023 | ||
| EP-4544068-A1 | Viral vector and producer cell | Pending | 30-Jun-2023 | ||
| ES-3055997-T3 | Viral vector and producer cell | Active | 30-Jun-2023 | C12N15/86 |
EsoBiotec Signals
EsoBiotec Former Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Carbon ( Belgium ) | Venture Capital | Minority | ||
| Invivo Partners | Venture Capital | Minority | ||
| ORSA FUND | Venture Capital | Minority | ||
| Société Régionale d'Investissement de Wallonie | Growth/Expansion | Minority | ||
| Thuja Capital Management | Venture Capital | Minority |
EsoBiotec FAQs
-
When was EsoBiotec founded?
EsoBiotec was founded in 2020.
-
Where is EsoBiotec headquartered?
EsoBiotec is headquartered in Charleroi, Belgium.
-
What is the size of EsoBiotec?
EsoBiotec has 12 total employees.
-
What industry is EsoBiotec in?
EsoBiotec’s primary industry is Biotechnology.
-
Is EsoBiotec a private or public company?
EsoBiotec is a Private company.
-
What is the current valuation of EsoBiotec?
The current valuation of EsoBiotec is .
-
What is EsoBiotec’s current revenue?
The current revenue for EsoBiotec is .
-
How much funding has EsoBiotec raised over time?
EsoBiotec has raised $20.9M.
-
Who are EsoBiotec’s investors?
Carbon ( Belgium ), Invivo Partners, ORSA FUND, Société Régionale d'Investissement de Wallonie, and Thuja Capital Management are 5 of 8 investors who have invested in EsoBiotec.
-
When was EsoBiotec acquired?
EsoBiotec was acquired on 19-May-2025.
-
Who acquired EsoBiotec?
EsoBiotec was acquired by AstraZeneca.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process